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Abstract
Background: Healthcare costs, particularly pharmaceutical costs, are a dominant issue for most healthcare organizations,
but it is unclear if randomized controlled trials (RCTs) routinely discuss costs. Our objective was to assess the frequency and
factors associated with the inclusion of costs in RCTs.
Methods and Findings: We randomly sampled 188 RCTs spanning three years (2003-2005) from six high impact journals.
The sample size for RCTs was based on a calculation to estimate the inclusion of actual drug costs with a precision of
+/23%.Two reviewers independently extracted cost data and study characteristics.Frequencies were calculated and potential
characteristics associated with the inclusion of costs were explored. Actual drug costs were included in 4.7% (9/188) of RCTs;
any actual costs were included in 7.4% (14/188) of RCTs; and any mention of costs was included in 27.7% (52/188) of RCTs. As
the amount of industry funding increased across RCTs, from non-profit to mixed to fully industry funded RCTs, there was a
statistically significant reduction in the number of RCTs with any actual costs (Cochran-Armitage test, p=0.005) and any
mention of costs (Cochran-Armitage test, p=0.02). Logistic regression analysis also indicated funding was associated with the
inclusionof any actual cost(OR=0.34, p=0.009)or any mention of costs (OR=0.63, p=0.02).Journal, study conclusions, study
location, primary author’s country and product age were not associated with inclusion of cost information.
Conclusion: While physicians are encouraged to consider costs when prescribing drugs for their patients, actual drug costs
were provided in only 5% of RCTs and were not mentioned at all in 72% of RCTs. Industry funded trials were less likely to
include cost information. No other factors were associated with the inclusion of cost information.
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Introduction
The costs of pharmaceuticals in almost all countries of the
Organisation for Economic Co-operation and Development
(OECD) are increasing faster than any other aspect of healthcare
budgets [1]. Many countries struggle with a wide variety of
strategies to reduce or control pharmaceutical spending [2,3], but
many approaches increase drug costs for patients, often worsen
outcomes and shift costs to other areas [4–8]. Surveys have found
that physicians consider health care costs to be important when
prescribing, even when patients have full drug coverage [9–11].
Other studies have observed that physicians’ prescribing was
responsive to price when costs were made available to them [12–
14]. A number of studies in the clinical setting have found that
prescribing costs declined without negative impacts on care if
physicians were given feedback about their prescribing costs
and provided with cost information [15–17]. Ideally, physi-
cians would select less expensive products if the alternatives were
equally efficacious. Unfortunately, physicians have a very limited
understanding of drug cost and, more importantly, do not
understand the large cost differential between expensive and
inexpensive drugs [18].
Physicians have indicated they want more cost information [18],
although several researchers have reported that cost information
was difficult to obtain [19,20]. Currently, there are no data
quantifying the availability of this information in the medical
literature.
Our objective was to determine how often actual drug costs and
healthcare costs in general were included in randomized
controlled trials (RCTs) and to identify the factors that may be
associated with the inclusion of cost information in RCTs.
Methods
Although there are no established templates for studies assessing
reporting in the literature, PRISMA [21], the guide for reporting
of systematic reviews, serves as a reasonable model and was
followed where possible.
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Our study was limited to RCTs, the gold-standard of therapy
evidence. To address the inclusion of drug costs, only RCTs
comparing a pharmaceutical to no treatment, placebo or active
control were eligible.
Information Sources
Similar to past studies that assessed reporting in the literature
[22,23], we used six major general medical journals to sample
RCTs: New England Journal of Medicine (N Eng J Med), Journal
of the American Medical Association (JAMA), Lancet, British
Medical Journal (BMJ), Annals of Internal Medicine (Ann Intern
Med) and Archives of Internal Medicine (Arch Intern Med).
Search
We used PubMed to identify all RCTs. A search was performed
in May 2006 using the abbreviated journal title restricted to the
date range January 1 to December 31 for each individual year
(2003, 2004 or 2005) and Randomized Controlled Trial for type of
article. For example, to search for RCTs published in the N Engl J
Med in 2005, we entered N Engl J Med in the search bar and
limited the search to RCTs under type of article and the dates to
January 1, 2005 to December 31, 2005. To confirm these searches
captured all the RCTs published in journals, we reviewed each
issue from two of journals for 2005 and found none were missed.
The PubMed search did capture a few articles that were not RCTs
but these were identified during review for inclusion.
Study Selection
The total number of articles found in each search of article type,
journal and year (e.g., RCTs in N Engl J Med in 2005) was used to
generate the randomization for that group. Randomization was
performed using Excel.
The sample size was based on our objective to obtain an
accurate and precise estimate of reporting of actual drug costs in
RCTs. Initially, 10 articles were randomly selected from each of
the six journals published in the year 2005. An interim analysis of
those 60 RCTs found that actual drug costs were reported in less
than 5% of the RCTs. To attain a precision of +/2 3% with a
95% Confidence Interval (CI), 188 RCTs had to be reviewed,
assuming the reporting of actual cost was #5%. In addition to 10
RCTs from 2005 from each journal, 10 RCTs were randomly
selected from each journal for the years 2003 and 2004. Eight
more studies were randomly selected from any of the included
years or journals.
The abstract of each article randomly selected was reviewed to
confirm it met the eligibility criteria: an RCT that assessed
pharmaceutical therapy. If it did not, a random number was again
generated to choose a replacement RCT.
Data Abstraction
To identify cost information, two authors (GMA & KL)
independently searched each RCT with the Adobe Reader Search
function using the key words ‘‘cost’’, ‘‘pric’’, ‘‘$’’, ‘‘dollar’’,
‘‘pound’’, ‘‘£’’, ‘‘money’’, ‘‘fee’’, ‘‘fund’’, ‘‘econom’’, ‘‘financ’’,
and ‘‘expens’’. One author (KL) also read each RCT for any
mention or discussion of costs. We classified costs in to three
categories: actual drug costs, any actual costs, and any mention of
costs. ‘Actual drug costs’ were any specific drug cost provided as a
numeric value in dollars, pounds or other currency. ‘Any actual
costs’ were any drug cost and/or any healthcare cost provided as a
numeric value in dollars, pounds or other currency. ‘Any mention
of costs’ was considered any of the above plus any discussion of
health care costs, no matter how general (e.g. the management of
this condition is very expensive). We limited counting ‘any
mention of costs’ to once per paragraph when costs were discussed
without numeric values. This was because a single paragraph may
have frequently included words such as ‘‘cost’’, ‘‘expense’’, or
‘‘economic’’, but the rest of the article had no other discussion of
costs. We did not count costs relating to expenses of the trial (e.g.
‘‘we paid participants $5 to complete the testing’’), funding sources
or financial conflict of interest. Finally, we did not count costs-
associated words appearing in reference sections.
Two authors (GMA and CK) independently abstracted data on
RCT characteristics: experimental drug, age of the experimental
drug (novel or established), the comparator, funding of the trial,
study country, primary author’s country and conclusion. We
defined the age of the experimental drug as ‘‘novel’’ if it was still
on-patent at the time of the study and as ‘‘established’’ if it was off-
patent at the time of the study. Funding was divided into
categories of industry, non-profit or mixed. Funding was classified
as mixed if the study had both non-profit and industry funding
sources. If a study had any industry funding, even if only supplying
the pharmaceutical product, it was classified as mixed. We found
that classifying conclusions as simply ‘‘positive’’ or ‘‘negative’’ did
not reflect the range of language used by authors to explain
their results. Therefore, we modified the classification used by
Kjaergard and Als-Nielsen [24] by shortening their ranking of 6
into 4 (combining the ranks of 5 & 4 and 2 & 3). Our four options
were: Positive, Positive But, Negative But and Negative. Any
disagreements were resolved with discussion and consensus. The
data abstraction template is available in Appendix S1. In
extracting cost information, we originally had more sub-categories
but found the frequency of cost reporting so infrequent it did not
warrant multiple sub-categories.
Data Analysis
Similar to previous studies [25,26] that assessed reporting in the
literature, we compared the data extraction from a sample of the
RCTs to determine inter-rater agreement. We used the abstrac-
tion data from two journals (63 RCTs) to compare general
agreement over cost and RCT characteristics. We also assessed the
Kappa values for areas with a higher potential for disagreement: the
age of the experimental drug (novel or established), funding of the
trial and conclusion.
We summarized the results to provide a descriptive analysis
including overall mean percent of studies which had actual drug
costs, any actual costs and any mention of costs, with 95% CI. We
originally intended to compare the inclusion of actual drug costs or
any mention of costs across different study characteristics (e.g.,
funding or product age). However, RCTs with actual drug costs
were so few in number that we opted to analyze any actual costs
(actual drug costs or any other healthcare cost with numeric value
in a dollars, pounds or any currency) and any mention of cost. We
used Fisher-Freeman-Halton test for nominal data to compare the
number of RCTs that included actual costs and any mention of
costs associated with different journals, primary author’s country
or study location. We used Cochran-Armitage test for ordinal data
to compare the number of RCTs that included actual costs and
any mention of costs associated with funding and study con-
clusions. We used Fisher’s Exact Test to compare the number of
RCTs that included actual costs and any mention of costs
associated with product age (novel or established). We also did a
logistic regression to compare the dependant variables of actual
cost and mention of cost simultaneously with the independent
variables of funding, conclusion, primary author’s country, and
product age.
Are Costs Discussed in RCTs
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A total of 188 RCTs were reviewed (a full list is available in
Appendix S2). Disagreement between reviewers was uncommon.
From a sample of 63 RCTs (from two journals), agreement in
extracting cost information was 94% and agreement in extraction
for RCT variables (such as funding, outcomes, etc) was 91%. The
Kappa values for the age of the experimental drug (novel or
established) was 0.87, funding of the trial 0.74, and the conclusion
0.75. All disagreements were resolved with discussion.
Table 1 reports how often costs were mentioned in RCTs. The
number of RCTs with actual drug costs in dollars, pounds or other
currency was 9 of 188 or 4.7% (95% CI, 1.7%–7.7%). The
number of RCTs with any actual cost (of drugs and/or other
healthcare in dollars, pounds or other currencies) was 14 of 188 or
7.4% (95% CI, 3.7%–11.1%), varying among the journals from
3% (1/32) to 19% (6/32) although the difference was not
statistically significant (Fisher-Freeman-Halton test, p=0.17).
The number of RCTs with any mention of costs was 52 of 188
or 27.7% (95% CI, 20.6%–33.3%), varying among the journals
from 23% (7/31) to 31% (10/32), although the difference was not
statistically significant (Fisher-Freeman-Halton test, p=0.97).
Costs were mentioned 166 times in the RCTs for a mean of 0.9
mentions per RCT. However, the median number of times that
cost was mentioned was 0 because 72% of RCTs did not include
any costs. Of the RCTs with any mention of costs (52 of 188),
there was an average of 3.2 mentions per RCT and a median of
1.5 mentions per RCT. Half (26 of 52) of the RCTs including costs
only mentioned them once. Six of the 188 RCTs had 10 or more
(maximum 21) mentions of costs per article and account for 90 of
the 166 mentions overall. Therefore, 3% of the articles account for
54% of the total number of times that costs were mentioned.
Table 2 provides the frequency of costs mentioned in RCTs
grouped by study characteristics. Comparing RCTs based on
funding, there was a statistically significant reduction in the
number of RCTs including any actual costs (Cochran-Armitage
test, p=0.005) and any mention of costs (Cochran-Armitage test,
p=0.02) from non-profit to mixed to industry funded studies.
Compared to RCTs of novel drugs, RCTs of established drugs
were significantly more likely to include any actual costs (fisher’s
exact test, p=0.02), although were not more likely to include any
mention of costs (fisher’s exact test, p=0.51).
Logistic regression analysis indicated that funding was the only
factor associated with the inclusion of any actual cost (OR=0.34,
p=0.009) or any mention of costs (OR=0.63, p=0.02). None of
the other independent variables (conclusion, product age or
primary author’s country) were significantly associated with the
inclusion of any actual cost or any mention of costs. The significant
result of product age associated with the inclusion of any actual
cost disappeared in regression analysis, suggesting that the
inclusion of any actual costs with product age may be attributed
to the correlation between product age and funding (i.e., industry
funded RCTs would more likely to study novel drugs still on
patent). The correlation coefficient between these two variables
was high at 0.54, while no other two variables in the regression
analysis had a correlation higher than 0.13.
Discussion
Healthcare costs were mentioned in only 28% of RCTs of
pharmaceutical therapy and actual drug costs were rarely (5%)
included. The User’s Guide to the Medical Literature [27]
suggests that costs be considered in the application of all study
results. Furthermore, most physicians believe that costs should be
considered in clinical decision-making [9–11]. Unfortunately,
physicians do not know the costs of drugs [18] or other healthcare
interventions [28]. Therefore, if clinicians were to consider costs in
evaluating application of an RCT result, the drug cost would have
to be included in the paper. It might be argued that physicians
could access the costs elsewhere, although some authors have
reported accurate costs are difficult to find [19,20]. The inclusion
of costs, even a brief mention, would not be onerous and would
help physicians consider and compare the relative benefit of a drug
in relation to its’ cost.
The total number of times costs were mentioned (166 times)
appears to be relatively high, but this number is inflated by a few
studies with cost as their primary focus. For example, a Lancet
article includes costs 20 times which is equal to or more than all
the articles from three of the other journals. We felt that these
differences did not warrant statistical testing among the journals as
the number of RCTs with any mention of cost did not differ
among journals. Additionally, any differences between the total
number of mentions could be due to chance since only 3% (6/188)
of the RCTs provided 54% (90/166) of the total number of times
costs were mentioned. Cost was a focus of these articles in contrast
to the other 97% (182/188) of the RCTs.
Inclusion of healthcare costs did not vary by journal, primary
author’s country, study location, product age or conclusion.
Although the inclusion of any actual cost was statistically less
common in established (or older) drugs compared to novel (or
newer), this finding disappeared on logistic regression. The
association to product age and the inclusion of any actual cost
was due to the correlation of funding and product age. Funding
appears to be the only factor associated with the inclusion of cost
Table 1. Inclusion of drug costs, health care cost or any mention of cost in Randomized Controlled Trials.
Number of articles
with actual drug cost*
Number of articles
with any actual cost*
Number of articles with
any mention of costs
Total number of times
costs mentioned
JAMA (31) 1 (3%) 2 (6%) 8 (26%) 15
N Engl J Med (32) 0 1 (3%) 10 (31%) 33
Lancet (32) 5 (16%) 6 (19%) 10 (31%) 59
BMJ (30) 2 (7%) 3 (10%) 8 (27%) 20
Ann Intern Med (31) 0 1 (3%) 7 (23%) 23
Arch Intern Med (32) 1 (3%) 1 (3%) 9 (28%) 16
TOTAL (188) 9 (4.7%) 14 (7.4%) 52 (27.7%) 166
*Actual drug cost and any actual cost means there was a cost with a numeric value in dollars, pounds or other currency.
doi:10.1371/journal.pone.0012318.t001
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mention of cost in bi-variant analysis and multi-variant analysis of
logistic regression. Industry funded studies were significantly less
likely to mention costs than studies funded solely from non-profit
sources. In fact, the likelihood that cost information was included
in RCTs increased as the degree of industry funding declined.
RCTs with any mention of costs increased across funding groups:
from industry (18%) to mixed (31%) to non-profit (36%). This
pattern was consistent with the inclusion of any actual costs: from
industry (1%) to mixed (7%) to non-profit (15%) funding.
In light of previous studies showing that funding was associated
with study conclusion [22–24,29,30], it may be reasonable to
conclude thatfunding could also beassociated with thewriting ofthe
articles. It is possible that authors of industry-funded trials avoid
discussionofcostsbecausetheirproductsareusuallymoreexpensive.
However, it is also possible that the authors of non-profit funded
trials are more likely to include a discussion of costs because they feel
obliged to consider costs as many non-profit sources (like
government-linked sponsors) may be more cost-conscious.
A potential limitation of the study is the four-year delay from
search to submission as cost reporting may have changed in that
time. This is, however, highly unlikely as no incentive or initiative
has been introduced to trigger such as change. Our journal
selection may have impacted our results, particularly compared to
journals with a health economic focus. Additionally, we included
only RCTs — other types of articles may have included more cost
information. That said, our goal was to examine clinically relevant
RCTs in high impact clinical journals that are more often read
and used by clinicians. As data extraction required some
interpretation, particularly for the subjective areas such as study
conclusion, there is the potential that different raters would
categorize the conclusions differently. Our level of agreement was
similar to investigators in previous studies assessing reporting in
the literature. Our Kappa ranged from 0.87 to 0.74 while Pitkin et al
[25] reported a 0.81 Kappa and Moher et al [26] report a Kappa
values between 1 and 0.53.
Future research should examine other medical information
resources, such as internet evidence-based summarized sites, other
types of articles and perhaps other journals. If other resources
provide cost information, the accuracy of the information should
be examined, although defining true cost and accounting for cost
difference over time and different locations will be challenging.
In summary, actual drug costs or any actual costs are rarely
included in RCTs and costs are not mentioned at all in 72% of
RCTs. Trials funded from non-profit sources were more likely to
include cost information compared to trials with solely industry
based funding. No other factors were associated with cost
inclusion. More work is needed to provide physicians with the
cost information that can inform their decision-making and
potentially reduce healthcare costs.
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Table 2. Study characteristics associated with costs being mentioned in Randomized Controlled Trials.
Total
number
Number of Studies
with Actual
Costs (%)
Statistical
Testing
Number of Studies
Mentioning
Costs (%)
Statistical
Testing
Funding Industry 68 1 (1%) p=0.005* 12 (18%) p=0.02*
Mixed 67 5 (7%) 21 (31%)
Non-profit 53 8 (15%) 19 (36%)
Conclusion Negative 37 5 (14%) p=0.16* 13 (35%) p=0.49*
Negative But 14 1 (7%) 3 (21%)
Positive But 34 2 (6%) 8 (24%)
Positive 103 6 (6%) 28 (27%)
Primary Author’s Country United States 86 4 (5%) p=0.12
{ 25 (29%) p=0.52
{
Europe 72 5 (7%) 17 (24%)
Other 30 5 (17%) 10 (33%)
Study Location Multi-centered 53 3 (6%) p=0.59
{ 11 (21%) p=0.61
{
United States 57 3 (5%) 16 (28%)
Europe 39 3 (8%) 12 (31%)
Developing Countries 21 3 (14%) 8 (38%)
Other 18 2 (11%) 5 (28%)
Product Age Novel 109 4 (4%) p=0.02
{ 28 (26%) p=0.51
{
Established 79 10 (13%) 24 (30%)
*Cochran-Armitage test.
{Fisher-Freeman-Halton test.
{Fisher’s exact test.
doi:10.1371/journal.pone.0012318.t002
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